www.fdanews.com/articles/75454-kosan-terminates-offering-after-stock-decline
KOSAN TERMINATES OFFERING AFTER STOCK DECLINE
August 17, 2005
Kosan Biosciences Inc. (KOSN.O: Quote, Profile, Research) said it terminated its previously announced 4.5 million common stock offering after the 17 percent decline in its stock earlier on Monday. The company's shares closed down $1.51 to $7.35 on the Nasdaq after the National Cancer Institute announced it would amend clinical trial protocols for two cancer therapies, forms of which Kosan is also testing, after five patients showed slight changes in heartbeat after treatment.